nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—ALB—Auranofin—psoriatic arthritis	0.16	0.217	CbGbCtD
Gefitinib—ALB—Prednisone—psoriatic arthritis	0.051	0.069	CbGbCtD
Gefitinib—ABCG2—Dexamethasone—psoriatic arthritis	0.0462	0.0625	CbGbCtD
Gefitinib—ABCB1—Methylprednisolone—psoriatic arthritis	0.0441	0.0596	CbGbCtD
Gefitinib—CYP1A1—Dexamethasone—psoriatic arthritis	0.0427	0.0577	CbGbCtD
Gefitinib—ABCG2—Methotrexate—psoriatic arthritis	0.0371	0.0502	CbGbCtD
Gefitinib—CYP2C19—Prednisone—psoriatic arthritis	0.0331	0.0447	CbGbCtD
Gefitinib—ABCB1—Betamethasone—psoriatic arthritis	0.0286	0.0387	CbGbCtD
Gefitinib—ABCB1—Prednisolone—psoriatic arthritis	0.0283	0.0382	CbGbCtD
Gefitinib—ABCB1—Prednisone—psoriatic arthritis	0.0267	0.0361	CbGbCtD
Gefitinib—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0264	0.0357	CbGbCtD
Gefitinib—CYP3A5—Dexamethasone—psoriatic arthritis	0.0256	0.0346	CbGbCtD
Gefitinib—ALB—Methotrexate—psoriatic arthritis	0.0256	0.0346	CbGbCtD
Gefitinib—CYP2C19—Dexamethasone—psoriatic arthritis	0.0207	0.0279	CbGbCtD
Gefitinib—CYP3A4—Triamcinolone—psoriatic arthritis	0.02	0.0271	CbGbCtD
Gefitinib—CYP2C9—Dexamethasone—psoriatic arthritis	0.0172	0.0232	CbGbCtD
Gefitinib—CYP3A4—Betamethasone—psoriatic arthritis	0.0172	0.0232	CbGbCtD
Gefitinib—CYP3A4—Prednisolone—psoriatic arthritis	0.0169	0.0229	CbGbCtD
Gefitinib—ABCB1—Dexamethasone—psoriatic arthritis	0.0167	0.0225	CbGbCtD
Gefitinib—CYP3A4—Prednisone—psoriatic arthritis	0.016	0.0216	CbGbCtD
Gefitinib—CYP2D6—Dexamethasone—psoriatic arthritis	0.0157	0.0212	CbGbCtD
Gefitinib—ABCB1—Methotrexate—psoriatic arthritis	0.0134	0.0181	CbGbCtD
Gefitinib—CYP3A4—Dexamethasone—psoriatic arthritis	0.00998	0.0135	CbGbCtD
Gefitinib—ERBB3—Apoptosis-related network due to altered Notch3 in ovarian cancer—CARD14—psoriatic arthritis	0.00482	0.0882	CbGpPWpGaD
Gefitinib—IRAK1—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—MEFV—psoriatic arthritis	0.00205	0.0376	CbGpPWpGaD
Gefitinib—IRAK1—JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1—NOD2—psoriatic arthritis	0.00192	0.0352	CbGpPWpGaD
Gefitinib—IRAK1—activated TAK1 mediates p38 MAPK activation—NOD2—psoriatic arthritis	0.00183	0.0335	CbGpPWpGaD
Gefitinib—IRAK4—IL-1 signaling pathway—REL—psoriatic arthritis	0.00159	0.0292	CbGpPWpGaD
Gefitinib—IRAK4—Interleukin-1 signaling—NOD2—psoriatic arthritis	0.00139	0.0255	CbGpPWpGaD
Gefitinib—MKNK1—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriatic arthritis	0.00135	0.0247	CbGpPWpGaD
Gefitinib—IRAK1—TAK1 activates NFkB by phosphorylation and activation of IKKs complex—NOD2—psoriatic arthritis	0.0013	0.0239	CbGpPWpGaD
Gefitinib—IRAK1—NOD1/2 Signaling Pathway—NOD2—psoriatic arthritis	0.00113	0.0207	CbGpPWpGaD
Gefitinib—IRAK1—IL-1 signaling pathway—REL—psoriatic arthritis	0.00106	0.0194	CbGpPWpGaD
Gefitinib—IRAK1—Interleukin-1 signaling—NOD2—psoriatic arthritis	0.000924	0.0169	CbGpPWpGaD
Gefitinib—CSNK1E—Danazol—Prednisone—psoriatic arthritis	0.000873	0.123	CbGdCrCtD
Gefitinib—Ulcer—Prednisone—psoriatic arthritis	0.000855	0.0043	CcSEcCtD
Gefitinib—Diarrhoea—Auranofin—psoriatic arthritis	0.000852	0.00429	CcSEcCtD
Gefitinib—Dermatitis bullous—Prednisolone—psoriatic arthritis	0.000845	0.00425	CcSEcCtD
Gefitinib—Vomiting—Auranofin—psoriatic arthritis	0.000792	0.00398	CcSEcCtD
Gefitinib—Rash—Auranofin—psoriatic arthritis	0.000785	0.00395	CcSEcCtD
Gefitinib—Dermatitis—Auranofin—psoriatic arthritis	0.000785	0.00395	CcSEcCtD
Gefitinib—Thrombophlebitis—Dexamethasone—psoriatic arthritis	0.000779	0.00392	CcSEcCtD
Gefitinib—Thrombophlebitis—Betamethasone—psoriatic arthritis	0.000779	0.00392	CcSEcCtD
Gefitinib—Dermatitis bullous—Triamcinolone—psoriatic arthritis	0.000777	0.00391	CcSEcCtD
Gefitinib—IRAK1—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—psoriatic arthritis	0.000773	0.0141	CbGpPWpGaD
Gefitinib—Proteinuria—Methotrexate—psoriatic arthritis	0.000769	0.00387	CcSEcCtD
Gefitinib—IRAK4—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000762	0.0139	CbGpPWpGaD
Gefitinib—IRAK4—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.000761	0.0139	CbGpPWpGaD
Gefitinib—Protein urine present—Methotrexate—psoriatic arthritis	0.000759	0.00382	CcSEcCtD
Gefitinib—IRAK4—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.000755	0.0138	CbGpPWpGaD
Gefitinib—Eye pain—Betamethasone—psoriatic arthritis	0.000747	0.00376	CcSEcCtD
Gefitinib—Eye pain—Dexamethasone—psoriatic arthritis	0.000747	0.00376	CcSEcCtD
Gefitinib—IRAK4—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.000741	0.0136	CbGpPWpGaD
Gefitinib—Dry skin—Prednisolone—psoriatic arthritis	0.000741	0.00373	CcSEcCtD
Gefitinib—Nausea—Auranofin—psoriatic arthritis	0.00074	0.00372	CcSEcCtD
Gefitinib—IRAK4—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.000715	0.0131	CbGpPWpGaD
Gefitinib—Ulcer—Methotrexate—psoriatic arthritis	0.000715	0.0036	CcSEcCtD
Gefitinib—IRAK1—MAP kinase activation in TLR cascade—NOD2—psoriatic arthritis	0.000706	0.0129	CbGpPWpGaD
Gefitinib—Dermatitis bullous—Dexamethasone—psoriatic arthritis	0.000705	0.00355	CcSEcCtD
Gefitinib—Dermatitis bullous—Betamethasone—psoriatic arthritis	0.000705	0.00355	CcSEcCtD
Gefitinib—IRAK4—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000703	0.0129	CbGpPWpGaD
Gefitinib—Respiratory failure—Methotrexate—psoriatic arthritis	0.000688	0.00346	CcSEcCtD
Gefitinib—Pancreatitis—Prednisolone—psoriatic arthritis	0.000685	0.00344	CcSEcCtD
Gefitinib—Thrombophlebitis—Prednisone—psoriatic arthritis	0.000678	0.00341	CcSEcCtD
Gefitinib—IRAK1—Apoptosis Modulation and Signaling—TNFRSF1B—psoriatic arthritis	0.000668	0.0122	CbGpPWpGaD
Gefitinib—Melaena—Methotrexate—psoriatic arthritis	0.00066	0.00332	CcSEcCtD
Gefitinib—Cystitis noninfective—Methotrexate—psoriatic arthritis	0.00066	0.00332	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Methylprednisolone—psoriatic arthritis	0.000654	0.00329	CcSEcCtD
Gefitinib—Cystitis—Methotrexate—psoriatic arthritis	0.000653	0.00328	CcSEcCtD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.000639	0.0117	CbGpPWpGaD
Gefitinib—Pancreatitis—Triamcinolone—psoriatic arthritis	0.00063	0.00317	CcSEcCtD
Gefitinib—IRAK4—Signaling by Interleukins—NOD2—psoriatic arthritis	0.000629	0.0115	CbGpPWpGaD
Gefitinib—Pancreatitis—Methylprednisolone—psoriatic arthritis	0.000628	0.00316	CcSEcCtD
Gefitinib—Dry skin—Betamethasone—psoriatic arthritis	0.000618	0.00311	CcSEcCtD
Gefitinib—Dry skin—Dexamethasone—psoriatic arthritis	0.000618	0.00311	CcSEcCtD
Gefitinib—Hypokalaemia—Betamethasone—psoriatic arthritis	0.000614	0.00309	CcSEcCtD
Gefitinib—Hypokalaemia—Dexamethasone—psoriatic arthritis	0.000614	0.00309	CcSEcCtD
Gefitinib—Bladder pain—Methotrexate—psoriatic arthritis	0.000611	0.00307	CcSEcCtD
Gefitinib—Mouth ulceration—Methotrexate—psoriatic arthritis	0.000611	0.00307	CcSEcCtD
Gefitinib—CSNK1E—Dexamethasone—Methylprednisolone—psoriatic arthritis	0.00061	0.0858	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Methylprednisolone—psoriatic arthritis	0.00061	0.0858	CbGdCrCtD
Gefitinib—IRAK4—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.000607	0.0111	CbGpPWpGaD
Gefitinib—Conjunctivitis—Prednisolone—psoriatic arthritis	0.000605	0.00304	CcSEcCtD
Gefitinib—IRAK4—AGE/RAGE pathway—NOS2—psoriatic arthritis	0.000605	0.0111	CbGpPWpGaD
Gefitinib—CSNK1E—Dexamethasone—Betamethasone—psoriatic arthritis	0.000601	0.0844	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Dexamethasone—psoriatic arthritis	0.000601	0.0844	CbGdCrCtD
Gefitinib—IRAK4—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.000594	0.0109	CbGpPWpGaD
Gefitinib—CSNK1E—Betamethasone—Triamcinolone—psoriatic arthritis	0.000587	0.0825	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Triamcinolone—psoriatic arthritis	0.000587	0.0825	CbGdCrCtD
Gefitinib—Infestation—Methylprednisolone—psoriatic arthritis	0.000571	0.00287	CcSEcCtD
Gefitinib—Infestation NOS—Methylprednisolone—psoriatic arthritis	0.000571	0.00287	CcSEcCtD
Gefitinib—IRAK4—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.000571	0.0104	CbGpPWpGaD
Gefitinib—Thrombophlebitis—Methotrexate—psoriatic arthritis	0.000567	0.00285	CcSEcCtD
Gefitinib—Haemoglobin—Prednisolone—psoriatic arthritis	0.000562	0.00283	CcSEcCtD
Gefitinib—IRAK1—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.000559	0.0102	CbGpPWpGaD
Gefitinib—Haemorrhage—Prednisolone—psoriatic arthritis	0.000559	0.00281	CcSEcCtD
Gefitinib—CSNK1E—Dexamethasone—Prednisone—psoriatic arthritis	0.000557	0.0783	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Prednisone—psoriatic arthritis	0.000557	0.0783	CbGdCrCtD
Gefitinib—Conjunctivitis—Triamcinolone—psoriatic arthritis	0.000557	0.0028	CcSEcCtD
Gefitinib—Hepatic failure—Methotrexate—psoriatic arthritis	0.000546	0.00275	CcSEcCtD
Gefitinib—CSNK1E—Dexamethasone—Prednisolone—psoriatic arthritis	0.000544	0.0764	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Prednisolone—psoriatic arthritis	0.000544	0.0764	CbGdCrCtD
Gefitinib—Epistaxis—Triamcinolone—psoriatic arthritis	0.00054	0.00272	CcSEcCtD
Gefitinib—Dry skin—Prednisone—psoriatic arthritis	0.000538	0.00271	CcSEcCtD
Gefitinib—Hypokalaemia—Prednisone—psoriatic arthritis	0.000534	0.00269	CcSEcCtD
Gefitinib—Weight decreased—Dexamethasone—psoriatic arthritis	0.000527	0.00265	CcSEcCtD
Gefitinib—Weight decreased—Betamethasone—psoriatic arthritis	0.000527	0.00265	CcSEcCtD
Gefitinib—ERBB3—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000523	0.00956	CbGpPWpGaD
Gefitinib—Dermatitis exfoliative—Methotrexate—psoriatic arthritis	0.00052	0.00262	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Prednisone—psoriatic arthritis	0.000518	0.00261	CcSEcCtD
Gefitinib—Haemoglobin—Triamcinolone—psoriatic arthritis	0.000517	0.0026	CcSEcCtD
Gefitinib—Haemoglobin—Methylprednisolone—psoriatic arthritis	0.000516	0.00259	CcSEcCtD
Gefitinib—Haemorrhage—Triamcinolone—psoriatic arthritis	0.000514	0.00259	CcSEcCtD
Gefitinib—Haemorrhage—Methylprednisolone—psoriatic arthritis	0.000513	0.00258	CcSEcCtD
Gefitinib—IRAK4—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000508	0.00929	CbGpPWpGaD
Gefitinib—IRAK1—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000506	0.00925	CbGpPWpGaD
Gefitinib—IRAK1—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.000505	0.00924	CbGpPWpGaD
Gefitinib—Conjunctivitis—Betamethasone—psoriatic arthritis	0.000505	0.00254	CcSEcCtD
Gefitinib—Conjunctivitis—Dexamethasone—psoriatic arthritis	0.000505	0.00254	CcSEcCtD
Gefitinib—IRAK1—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.000501	0.00916	CbGpPWpGaD
Gefitinib—Arrhythmia—Prednisolone—psoriatic arthritis	0.000499	0.00251	CcSEcCtD
Gefitinib—Pancreatitis—Prednisone—psoriatic arthritis	0.000498	0.0025	CcSEcCtD
Gefitinib—LOC400927-CSNK1E—Circadian rythm related genes—NOS2—psoriatic arthritis	0.000494	0.00904	CbGpPWpGaD
Gefitinib—IRAK1—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.000492	0.009	CbGpPWpGaD
Gefitinib—Eye disorder—Methylprednisolone—psoriatic arthritis	0.000479	0.00241	CcSEcCtD
Gefitinib—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.000476	0.00239	CcSEcCtD
Gefitinib—IRAK1—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.000475	0.00868	CbGpPWpGaD
Gefitinib—Haemoglobin—Dexamethasone—psoriatic arthritis	0.000469	0.00236	CcSEcCtD
Gefitinib—Haemoglobin—Betamethasone—psoriatic arthritis	0.000469	0.00236	CcSEcCtD
Gefitinib—IRAK1—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000467	0.00853	CbGpPWpGaD
Gefitinib—Haemorrhage—Dexamethasone—psoriatic arthritis	0.000466	0.00235	CcSEcCtD
Gefitinib—Haemorrhage—Betamethasone—psoriatic arthritis	0.000466	0.00235	CcSEcCtD
Gefitinib—Angiopathy—Methylprednisolone—psoriatic arthritis	0.000465	0.00234	CcSEcCtD
Gefitinib—IRAK1—EBV LMP1 signaling—TNF—psoriatic arthritis	0.000463	0.00847	CbGpPWpGaD
Gefitinib—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.000462	0.00233	CcSEcCtD
Gefitinib—ERBB3—B Cell Activation—REL—psoriatic arthritis	0.000462	0.00845	CbGpPWpGaD
Gefitinib—ERBB3—DAP12 interactions—HLA-C—psoriatic arthritis	0.000459	0.0084	CbGpPWpGaD
Gefitinib—Arrhythmia—Triamcinolone—psoriatic arthritis	0.000459	0.00231	CcSEcCtD
Gefitinib—Weight decreased—Prednisone—psoriatic arthritis	0.000459	0.00231	CcSEcCtD
Gefitinib—Arrhythmia—Methylprednisolone—psoriatic arthritis	0.000458	0.00231	CcSEcCtD
Gefitinib—IRAK1—MyD88-independent cascade—NOD2—psoriatic arthritis	0.000448	0.00819	CbGpPWpGaD
Gefitinib—CHEK2—Danazol—Prednisone—psoriatic arthritis	0.000447	0.0628	CbGdCrCtD
Gefitinib—Malnutrition—Methylprednisolone—psoriatic arthritis	0.000447	0.00225	CcSEcCtD
Gefitinib—Angioedema—Prednisolone—psoriatic arthritis	0.000445	0.00224	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Methotrexate—psoriatic arthritis	0.000442	0.00222	CcSEcCtD
Gefitinib—Malaise—Prednisolone—psoriatic arthritis	0.000439	0.00221	CcSEcCtD
Gefitinib—IRAK4—Innate Immune System—MEFV—psoriatic arthritis	0.000437	0.008	CbGpPWpGaD
Gefitinib—Eye disorder—Betamethasone—psoriatic arthritis	0.000436	0.00219	CcSEcCtD
Gefitinib—Eye disorder—Dexamethasone—psoriatic arthritis	0.000436	0.00219	CcSEcCtD
Gefitinib—Angiopathy—Betamethasone—psoriatic arthritis	0.000423	0.00213	CcSEcCtD
Gefitinib—Angiopathy—Dexamethasone—psoriatic arthritis	0.000423	0.00213	CcSEcCtD
Gefitinib—IRAK1—Signaling by Interleukins—NOD2—psoriatic arthritis	0.000418	0.00764	CbGpPWpGaD
Gefitinib—Arrhythmia—Betamethasone—psoriatic arthritis	0.000417	0.0021	CcSEcCtD
Gefitinib—Arrhythmia—Dexamethasone—psoriatic arthritis	0.000417	0.0021	CcSEcCtD
Gefitinib—Pancreatitis—Methotrexate—psoriatic arthritis	0.000416	0.00209	CcSEcCtD
Gefitinib—Alopecia—Dexamethasone—psoriatic arthritis	0.000412	0.00207	CcSEcCtD
Gefitinib—Alopecia—Betamethasone—psoriatic arthritis	0.000412	0.00207	CcSEcCtD
Gefitinib—Angioedema—Triamcinolone—psoriatic arthritis	0.000409	0.00206	CcSEcCtD
Gefitinib—Haemoglobin—Prednisone—psoriatic arthritis	0.000408	0.00205	CcSEcCtD
Gefitinib—Angioedema—Methylprednisolone—psoriatic arthritis	0.000408	0.00205	CcSEcCtD
Gefitinib—Haemorrhage—Prednisone—psoriatic arthritis	0.000406	0.00204	CcSEcCtD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.000404	0.00738	CbGpPWpGaD
Gefitinib—Malaise—Triamcinolone—psoriatic arthritis	0.000404	0.00203	CcSEcCtD
Gefitinib—IRAK1—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.000403	0.00736	CbGpPWpGaD
Gefitinib—Malaise—Methylprednisolone—psoriatic arthritis	0.000403	0.00203	CcSEcCtD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000399	0.0073	CbGpPWpGaD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.000395	0.00722	CbGpPWpGaD
Gefitinib—Shock—Prednisolone—psoriatic arthritis	0.000391	0.00197	CcSEcCtD
Gefitinib—Cough—Triamcinolone—psoriatic arthritis	0.00039	0.00196	CcSEcCtD
Gefitinib—Pneumonia—Methotrexate—psoriatic arthritis	0.00038	0.00191	CcSEcCtD
Gefitinib—Eye disorder—Prednisone—psoriatic arthritis	0.00038	0.00191	CcSEcCtD
Gefitinib—IRAK1—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.000379	0.00693	CbGpPWpGaD
Gefitinib—Infestation—Methotrexate—psoriatic arthritis	0.000378	0.0019	CcSEcCtD
Gefitinib—Infestation NOS—Methotrexate—psoriatic arthritis	0.000378	0.0019	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000378	0.0019	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.000375	0.00189	CcSEcCtD
Gefitinib—Dry mouth—Triamcinolone—psoriatic arthritis	0.000373	0.00187	CcSEcCtD
Gefitinib—Angioedema—Betamethasone—psoriatic arthritis	0.000371	0.00187	CcSEcCtD
Gefitinib—Angioedema—Dexamethasone—psoriatic arthritis	0.000371	0.00187	CcSEcCtD
Gefitinib—Stomatitis—Methotrexate—psoriatic arthritis	0.000369	0.00185	CcSEcCtD
Gefitinib—Angiopathy—Prednisone—psoriatic arthritis	0.000369	0.00185	CcSEcCtD
Gefitinib—Conjunctivitis—Methotrexate—psoriatic arthritis	0.000368	0.00185	CcSEcCtD
Gefitinib—Malaise—Dexamethasone—psoriatic arthritis	0.000366	0.00184	CcSEcCtD
Gefitinib—Malaise—Betamethasone—psoriatic arthritis	0.000366	0.00184	CcSEcCtD
Gefitinib—Arrhythmia—Prednisone—psoriatic arthritis	0.000363	0.00183	CcSEcCtD
Gefitinib—Infection—Triamcinolone—psoriatic arthritis	0.000363	0.00183	CcSEcCtD
Gefitinib—Infection—Methylprednisolone—psoriatic arthritis	0.000362	0.00182	CcSEcCtD
Gefitinib—Haematuria—Methotrexate—psoriatic arthritis	0.000361	0.00181	CcSEcCtD
Gefitinib—Shock—Triamcinolone—psoriatic arthritis	0.000359	0.00181	CcSEcCtD
Gefitinib—Alopecia—Prednisone—psoriatic arthritis	0.000359	0.00181	CcSEcCtD
Gefitinib—Shock—Methylprednisolone—psoriatic arthritis	0.000359	0.0018	CcSEcCtD
Gefitinib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000358	0.0018	CcSEcCtD
Gefitinib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000357	0.0018	CcSEcCtD
Gefitinib—Epistaxis—Methotrexate—psoriatic arthritis	0.000357	0.00179	CcSEcCtD
Gefitinib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000354	0.00178	CcSEcCtD
Gefitinib—Malnutrition—Prednisone—psoriatic arthritis	0.000354	0.00178	CcSEcCtD
Gefitinib—ERBB3—Innate Immune System—MEFV—psoriatic arthritis	0.000349	0.00638	CbGpPWpGaD
Gefitinib—Haemoglobin—Methotrexate—psoriatic arthritis	0.000341	0.00172	CcSEcCtD
Gefitinib—Hypotension—Methylprednisolone—psoriatic arthritis	0.000341	0.00171	CcSEcCtD
Gefitinib—Pain—Prednisolone—psoriatic arthritis	0.00034	0.00171	CcSEcCtD
Gefitinib—Hepatitis—Methotrexate—psoriatic arthritis	0.000339	0.00171	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—psoriatic arthritis	0.000339	0.00171	CcSEcCtD
Gefitinib—IRAK1—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000337	0.00617	CbGpPWpGaD
Gefitinib—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000335	0.00169	CcSEcCtD
Gefitinib—Urethral disorder—Methotrexate—psoriatic arthritis	0.000333	0.00167	CcSEcCtD
Gefitinib—Infection—Dexamethasone—psoriatic arthritis	0.000329	0.00166	CcSEcCtD
Gefitinib—Infection—Betamethasone—psoriatic arthritis	0.000329	0.00166	CcSEcCtD
Gefitinib—Anaemia—Prednisone—psoriatic arthritis	0.000327	0.00164	CcSEcCtD
Gefitinib—Shock—Dexamethasone—psoriatic arthritis	0.000326	0.00164	CcSEcCtD
Gefitinib—Shock—Betamethasone—psoriatic arthritis	0.000326	0.00164	CcSEcCtD
Gefitinib—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000326	0.00164	CcSEcCtD
Gefitinib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000325	0.00163	CcSEcCtD
Gefitinib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000325	0.00163	CcSEcCtD
Gefitinib—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000324	0.00163	CcSEcCtD
Gefitinib—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000324	0.00163	CcSEcCtD
Gefitinib—Angioedema—Prednisone—psoriatic arthritis	0.000323	0.00163	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—psoriatic arthritis	0.000321	0.00161	CcSEcCtD
Gefitinib—Malaise—Prednisone—psoriatic arthritis	0.000319	0.0016	CcSEcCtD
Gefitinib—Eye disorder—Methotrexate—psoriatic arthritis	0.000317	0.0016	CcSEcCtD
Gefitinib—Anorexia—Dexamethasone—psoriatic arthritis	0.000316	0.00159	CcSEcCtD
Gefitinib—Anorexia—Betamethasone—psoriatic arthritis	0.000316	0.00159	CcSEcCtD
Gefitinib—Urticaria—Prednisolone—psoriatic arthritis	0.000316	0.00159	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—psoriatic arthritis	0.000315	0.00158	CcSEcCtD
Gefitinib—Fatigue—Triamcinolone—psoriatic arthritis	0.000315	0.00158	CcSEcCtD
Gefitinib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000314	0.00158	CcSEcCtD
Gefitinib—Pain—Triamcinolone—psoriatic arthritis	0.000312	0.00157	CcSEcCtD
Gefitinib—Hypotension—Dexamethasone—psoriatic arthritis	0.00031	0.00156	CcSEcCtD
Gefitinib—Hypotension—Betamethasone—psoriatic arthritis	0.00031	0.00156	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—psoriatic arthritis	0.000308	0.00155	CcSEcCtD
Gefitinib—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000306	0.00154	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—psoriatic arthritis	0.0003	0.00151	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000299	0.0015	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000298	0.0015	CcSEcCtD
Gefitinib—Malnutrition—Methotrexate—psoriatic arthritis	0.000296	0.00149	CcSEcCtD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000294	0.00537	CbGpPWpGaD
Gefitinib—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000293	0.00147	CcSEcCtD
Gefitinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000291	0.00532	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—MEFV—psoriatic arthritis	0.00029	0.00531	CbGpPWpGaD
Gefitinib—Urticaria—Triamcinolone—psoriatic arthritis	0.00029	0.00146	CcSEcCtD
Gefitinib—Urticaria—Methylprednisolone—psoriatic arthritis	0.000289	0.00146	CcSEcCtD
Gefitinib—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000289	0.00145	CcSEcCtD
Gefitinib—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000288	0.00145	CcSEcCtD
Gefitinib—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000288	0.00145	CcSEcCtD
Gefitinib—Decreased appetite—Betamethasone—psoriatic arthritis	0.000288	0.00145	CcSEcCtD
Gefitinib—MAP2K5—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000287	0.00525	CbGpPWpGaD
Gefitinib—Infection—Prednisone—psoriatic arthritis	0.000287	0.00144	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000286	0.00144	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000286	0.00144	CcSEcCtD
Gefitinib—Fatigue—Betamethasone—psoriatic arthritis	0.000286	0.00144	CcSEcCtD
Gefitinib—Fatigue—Dexamethasone—psoriatic arthritis	0.000286	0.00144	CcSEcCtD
Gefitinib—ERBB3—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—psoriatic arthritis	0.000285	0.00522	CbGpPWpGaD
Gefitinib—Shock—Prednisone—psoriatic arthritis	0.000284	0.00143	CcSEcCtD
Gefitinib—Pain—Betamethasone—psoriatic arthritis	0.000283	0.00143	CcSEcCtD
Gefitinib—Pain—Dexamethasone—psoriatic arthritis	0.000283	0.00143	CcSEcCtD
Gefitinib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000283	0.00142	CcSEcCtD
Gefitinib—Skin disorder—Prednisone—psoriatic arthritis	0.00028	0.00141	CcSEcCtD
Gefitinib—Anorexia—Prednisone—psoriatic arthritis	0.000275	0.00138	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—psoriatic arthritis	0.000273	0.00137	CcSEcCtD
Gefitinib—ERBB3—DAP12 interactions—HLA-B—psoriatic arthritis	0.000272	0.00497	CbGpPWpGaD
Gefitinib—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000271	0.00136	CcSEcCtD
Gefitinib—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000271	0.00136	CcSEcCtD
Gefitinib—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.000269	0.00135	CcSEcCtD
Gefitinib—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000268	0.00135	CcSEcCtD
Gefitinib—EGFR—AGE/RAGE pathway—NOS2—psoriatic arthritis	0.000268	0.00491	CbGpPWpGaD
Gefitinib—Malaise—Methotrexate—psoriatic arthritis	0.000266	0.00134	CcSEcCtD
Gefitinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	0.000265	0.00485	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000265	0.00485	CbGpPWpGaD
Gefitinib—Urticaria—Betamethasone—psoriatic arthritis	0.000263	0.00132	CcSEcCtD
Gefitinib—Urticaria—Dexamethasone—psoriatic arthritis	0.000263	0.00132	CcSEcCtD
Gefitinib—Asthenia—Triamcinolone—psoriatic arthritis	0.000262	0.00132	CcSEcCtD
Gefitinib—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000262	0.00132	CcSEcCtD
Gefitinib—Abdominal pain—Betamethasone—psoriatic arthritis	0.000262	0.00132	CcSEcCtD
Gefitinib—Body temperature increased—Betamethasone—psoriatic arthritis	0.000262	0.00132	CcSEcCtD
Gefitinib—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000262	0.00132	CcSEcCtD
Gefitinib—Asthenia—Methylprednisolone—psoriatic arthritis	0.000261	0.00132	CcSEcCtD
Gefitinib—CSNK1E—Circadian rythm related genes—NOS2—psoriatic arthritis	0.00026	0.00475	CbGpPWpGaD
Gefitinib—Pruritus—Triamcinolone—psoriatic arthritis	0.000258	0.0013	CcSEcCtD
Gefitinib—Cough—Methotrexate—psoriatic arthritis	0.000258	0.0013	CcSEcCtD
Gefitinib—Pruritus—Methylprednisolone—psoriatic arthritis	0.000258	0.0013	CcSEcCtD
Gefitinib—EGFR—B Cell Activation—REL—psoriatic arthritis	0.000257	0.0047	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—HLA-C—psoriatic arthritis	0.000256	0.00468	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—MEFV—psoriatic arthritis	0.000255	0.00466	CbGpPWpGaD
Gefitinib—Decreased appetite—Prednisone—psoriatic arthritis	0.000251	0.00126	CcSEcCtD
Gefitinib—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000251	0.00458	CbGpPWpGaD
Gefitinib—Rash—Prednisolone—psoriatic arthritis	0.00025	0.00126	CcSEcCtD
Gefitinib—Dermatitis—Prednisolone—psoriatic arthritis	0.00025	0.00126	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.00025	0.00126	CcSEcCtD
Gefitinib—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000249	0.00125	CcSEcCtD
Gefitinib—Fatigue—Prednisone—psoriatic arthritis	0.000249	0.00125	CcSEcCtD
Gefitinib—Constipation—Prednisone—psoriatic arthritis	0.000247	0.00124	CcSEcCtD
Gefitinib—ABCB1—Allograft Rejection—HLA-C—psoriatic arthritis	0.000246	0.0045	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—IL13—psoriatic arthritis	0.000245	0.00447	CbGpPWpGaD
Gefitinib—Infection—Methotrexate—psoriatic arthritis	0.00024	0.00121	CcSEcCtD
Gefitinib—Asthenia—Betamethasone—psoriatic arthritis	0.000238	0.0012	CcSEcCtD
Gefitinib—Asthenia—Dexamethasone—psoriatic arthritis	0.000238	0.0012	CcSEcCtD
Gefitinib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000237	0.00119	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000236	0.00119	CcSEcCtD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000236	0.00432	CbGpPWpGaD
Gefitinib—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000236	0.00119	CcSEcCtD
Gefitinib—Nausea—Prednisolone—psoriatic arthritis	0.000236	0.00119	CcSEcCtD
Gefitinib—Pruritus—Dexamethasone—psoriatic arthritis	0.000234	0.00118	CcSEcCtD
Gefitinib—Pruritus—Betamethasone—psoriatic arthritis	0.000234	0.00118	CcSEcCtD
Gefitinib—Skin disorder—Methotrexate—psoriatic arthritis	0.000234	0.00118	CcSEcCtD
Gefitinib—Vomiting—Triamcinolone—psoriatic arthritis	0.000232	0.00117	CcSEcCtD
Gefitinib—Vomiting—Methylprednisolone—psoriatic arthritis	0.000232	0.00117	CcSEcCtD
Gefitinib—Rash—Triamcinolone—psoriatic arthritis	0.00023	0.00116	CcSEcCtD
Gefitinib—Dermatitis—Triamcinolone—psoriatic arthritis	0.00023	0.00116	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—psoriatic arthritis	0.00023	0.00116	CcSEcCtD
Gefitinib—Rash—Methylprednisolone—psoriatic arthritis	0.00023	0.00116	CcSEcCtD
Gefitinib—Dermatitis—Methylprednisolone—psoriatic arthritis	0.00023	0.00115	CcSEcCtD
Gefitinib—Urticaria—Prednisone—psoriatic arthritis	0.000229	0.00115	CcSEcCtD
Gefitinib—Abdominal pain—Prednisone—psoriatic arthritis	0.000228	0.00115	CcSEcCtD
Gefitinib—Body temperature increased—Prednisone—psoriatic arthritis	0.000228	0.00115	CcSEcCtD
Gefitinib—Diarrhoea—Betamethasone—psoriatic arthritis	0.000227	0.00114	CcSEcCtD
Gefitinib—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000227	0.00114	CcSEcCtD
Gefitinib—Hypotension—Methotrexate—psoriatic arthritis	0.000225	0.00113	CcSEcCtD
Gefitinib—ABCB1—Allograft Rejection—IL17A—psoriatic arthritis	0.000225	0.00412	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—HLA-C—psoriatic arthritis	0.000224	0.00409	CbGpPWpGaD
Gefitinib—Nausea—Triamcinolone—psoriatic arthritis	0.000217	0.00109	CcSEcCtD
Gefitinib—Nausea—Methylprednisolone—psoriatic arthritis	0.000216	0.00109	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—psoriatic arthritis	0.000215	0.00108	CcSEcCtD
Gefitinib—Hypersensitivity—Prednisone—psoriatic arthritis	0.000213	0.00107	CcSEcCtD
Gefitinib—IRAK4—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000212	0.00387	CbGpPWpGaD
Gefitinib—Vomiting—Dexamethasone—psoriatic arthritis	0.000211	0.00106	CcSEcCtD
Gefitinib—Vomiting—Betamethasone—psoriatic arthritis	0.000211	0.00106	CcSEcCtD
Gefitinib—Decreased appetite—Methotrexate—psoriatic arthritis	0.00021	0.00105	CcSEcCtD
Gefitinib—ABCB1—Allograft Rejection—IL12B—psoriatic arthritis	0.000209	0.00383	CbGpPWpGaD
Gefitinib—Rash—Dexamethasone—psoriatic arthritis	0.000209	0.00105	CcSEcCtD
Gefitinib—Rash—Betamethasone—psoriatic arthritis	0.000209	0.00105	CcSEcCtD
Gefitinib—Dermatitis—Dexamethasone—psoriatic arthritis	0.000209	0.00105	CcSEcCtD
Gefitinib—Dermatitis—Betamethasone—psoriatic arthritis	0.000209	0.00105	CcSEcCtD
Gefitinib—ALB—Vitamin B12 Metabolism—CRP—psoriatic arthritis	0.000208	0.00381	CbGpPWpGaD
Gefitinib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000208	0.00105	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—psoriatic arthritis	0.000208	0.00105	CcSEcCtD
Gefitinib—Asthenia—Prednisone—psoriatic arthritis	0.000207	0.00104	CcSEcCtD
Gefitinib—Pain—Methotrexate—psoriatic arthritis	0.000206	0.00104	CcSEcCtD
Gefitinib—MAP2K5—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000205	0.00374	CbGpPWpGaD
Gefitinib—Pruritus—Prednisone—psoriatic arthritis	0.000204	0.00103	CcSEcCtD
Gefitinib—ERBB3—Immune System—MEFV—psoriatic arthritis	0.000203	0.00371	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.0002	0.00365	CbGpPWpGaD
Gefitinib—Diarrhoea—Prednisone—psoriatic arthritis	0.000197	0.000993	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000197	0.000992	CcSEcCtD
Gefitinib—Nausea—Betamethasone—psoriatic arthritis	0.000197	0.00099	CcSEcCtD
Gefitinib—Nausea—Dexamethasone—psoriatic arthritis	0.000197	0.00099	CcSEcCtD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000195	0.00356	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—MEFV—psoriatic arthritis	0.000194	0.00355	CbGpPWpGaD
Gefitinib—Urticaria—Methotrexate—psoriatic arthritis	0.000192	0.000964	CcSEcCtD
Gefitinib—MKNK1—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000191	0.0035	CbGpPWpGaD
Gefitinib—Abdominal pain—Methotrexate—psoriatic arthritis	0.000191	0.000959	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—psoriatic arthritis	0.000191	0.000959	CcSEcCtD
Gefitinib—ERBB3—Adaptive Immune System—REL—psoriatic arthritis	0.000186	0.00341	CbGpPWpGaD
Gefitinib—Vomiting—Prednisone—psoriatic arthritis	0.000183	0.000923	CcSEcCtD
Gefitinib—Rash—Prednisone—psoriatic arthritis	0.000182	0.000915	CcSEcCtD
Gefitinib—Dermatitis—Prednisone—psoriatic arthritis	0.000182	0.000915	CcSEcCtD
Gefitinib—ERBB3—Innate Immune System—HLA-C—psoriatic arthritis	0.000179	0.00326	CbGpPWpGaD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000178	0.00325	CbGpPWpGaD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000178	0.00325	CbGpPWpGaD
Gefitinib—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000178	0.000894	CcSEcCtD
Gefitinib—Asthenia—Methotrexate—psoriatic arthritis	0.000173	0.000871	CcSEcCtD
Gefitinib—Nausea—Prednisone—psoriatic arthritis	0.000171	0.000862	CcSEcCtD
Gefitinib—ERBB3—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000171	0.00313	CbGpPWpGaD
Gefitinib—Pruritus—Methotrexate—psoriatic arthritis	0.000171	0.000858	CcSEcCtD
Gefitinib—ALB—Folate Metabolism—CRP—psoriatic arthritis	0.00017	0.0031	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—MEFV—psoriatic arthritis	0.000169	0.00309	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—NOS2—psoriatic arthritis	0.000169	0.00308	CbGpPWpGaD
Gefitinib—IRAK4—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000165	0.00302	CbGpPWpGaD
Gefitinib—Diarrhoea—Methotrexate—psoriatic arthritis	0.000165	0.00083	CcSEcCtD
Gefitinib—IRAK4—Innate Immune System—NOD2—psoriatic arthritis	0.000165	0.00301	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000157	0.00287	CbGpPWpGaD
Gefitinib—CHEK2—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000157	0.00286	CbGpPWpGaD
Gefitinib—Vomiting—Methotrexate—psoriatic arthritis	0.000153	0.000771	CcSEcCtD
Gefitinib—Rash—Methotrexate—psoriatic arthritis	0.000152	0.000765	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—psoriatic arthritis	0.000152	0.000764	CcSEcCtD
Gefitinib—EGFR—DAP12 interactions—HLA-B—psoriatic arthritis	0.000151	0.00277	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—HLA-C—psoriatic arthritis	0.000149	0.00272	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—HLA-B—psoriatic arthritis	0.000146	0.00266	CbGpPWpGaD
Gefitinib—Nausea—Methotrexate—psoriatic arthritis	0.000143	0.000721	CcSEcCtD
Gefitinib—IRAK4—Immune System—REL—psoriatic arthritis	0.000142	0.00259	CbGpPWpGaD
Gefitinib—IRAK1—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000141	0.00257	CbGpPWpGaD
Gefitinib—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000135	0.00248	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000135	0.00246	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000133	0.00243	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—HLA-B—psoriatic arthritis	0.000132	0.00242	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—NOD2—psoriatic arthritis	0.000131	0.0024	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-C—psoriatic arthritis	0.00013	0.00238	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—HLA-DRB1—psoriatic arthritis	0.000123	0.00225	CbGpPWpGaD
Gefitinib—MAP2K5—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000118	0.00215	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—CRP—psoriatic arthritis	0.000117	0.00214	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MEFV—psoriatic arthritis	0.000113	0.00207	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—REL—psoriatic arthritis	0.000113	0.00207	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000112	0.00206	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000112	0.00206	CbGpPWpGaD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.00011	0.00201	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—NOD2—psoriatic arthritis	0.000109	0.002	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—HLA-B—psoriatic arthritis	0.000106	0.00193	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-C—psoriatic arthritis	0.000104	0.0019	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—REL—psoriatic arthritis	0.000104	0.0019	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000101	0.00185	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HLA-C—psoriatic arthritis	9.94e-05	0.00182	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—NOD2—psoriatic arthritis	9.59e-05	0.00175	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-C—psoriatic arthritis	9.54e-05	0.00174	CbGpPWpGaD
Gefitinib—ALB—Vitamin B12 Metabolism—TNF—psoriatic arthritis	9.43e-05	0.00172	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—REL—psoriatic arthritis	9.41e-05	0.00172	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—CRP—psoriatic arthritis	9.33e-05	0.00171	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—HLA-B—psoriatic arthritis	8.79e-05	0.00161	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-C—psoriatic arthritis	8.66e-05	0.00158	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	8.58e-05	0.00157	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—TNF—psoriatic arthritis	8.37e-05	0.00153	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—CRP—psoriatic arthritis	7.77e-05	0.00142	CbGpPWpGaD
Gefitinib—MKNK1—Disease—NOS2—psoriatic arthritis	7.72e-05	0.00141	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-B—psoriatic arthritis	7.71e-05	0.00141	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—TNF—psoriatic arthritis	7.68e-05	0.0014	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—NOD2—psoriatic arthritis	7.65e-05	0.0014	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—TNF—psoriatic arthritis	7.44e-05	0.00136	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—NOD2—psoriatic arthritis	7.31e-05	0.00134	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CRP—psoriatic arthritis	6.82e-05	0.00125	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-DRB1—psoriatic arthritis	6.53e-05	0.00119	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—NOD2—psoriatic arthritis	6.37e-05	0.00116	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—TNF—psoriatic arthritis	6.31e-05	0.00115	CbGpPWpGaD
Gefitinib—EGFR—Immune System—REL—psoriatic arthritis	6.29e-05	0.00115	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-B—psoriatic arthritis	6.15e-05	0.00112	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—TNF—psoriatic arthritis	6.1e-05	0.00111	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—NOS2—psoriatic arthritis	6e-05	0.0011	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HLA-B—psoriatic arthritis	5.88e-05	0.00107	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—TNF—psoriatic arthritis	5.82e-05	0.00106	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-C—psoriatic arthritis	5.79e-05	0.00106	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	5.69e-05	0.00104	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-B—psoriatic arthritis	5.64e-05	0.00103	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CRP—psoriatic arthritis	5.43e-05	0.000994	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-DRB1—psoriatic arthritis	5.2e-05	0.000952	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CRP—psoriatic arthritis	5.19e-05	0.00095	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-B—psoriatic arthritis	5.12e-05	0.000936	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	4.78e-05	0.000873	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NOS2—psoriatic arthritis	4.58e-05	0.000837	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CRP—psoriatic arthritis	4.52e-05	0.000827	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-DRB1—psoriatic arthritis	4.33e-05	0.000792	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NOD2—psoriatic arthritis	4.26e-05	0.000778	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-B—psoriatic arthritis	3.42e-05	0.000626	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NOS2—psoriatic arthritis	3.03e-05	0.000554	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CRP—psoriatic arthritis	3.03e-05	0.000553	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-DRB1—psoriatic arthritis	2.9e-05	0.00053	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	2.87e-05	0.000526	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TNF—psoriatic arthritis	2.66e-05	0.000487	CbGpPWpGaD
Gefitinib—EGFR—Disease—NOS2—psoriatic arthritis	2.55e-05	0.000466	CbGpPWpGaD
